Biotech
From Lab Platform to Product: 3 Swiss Biotech Startups
DealBio tracks early-stage biotech startups across Europe and North America. These 3 Swiss startups are turning research platforms into products for protein analysis, human tissue modeling and rare-disease therapy.
- Switzerland
- Academic Research
- Research Tools
- Tissue Engineering
- Drug Delivery
Research-heavy biotech becomes investable when technical capability is translated into a product with a clear user, use case and evidence path. For these startups, that means turning academic science into tools, models or therapies that can move beyond the laboratory and into repeatable commercial development.
UNOMR, Asemblis and NanoZymeX each show that transition already taking shape. The shared signal is movement from research capability toward a defined product, with clearer users, development milestones and evidence requirements.
At a Glance
01
UNOMR
Building nanopore sensors that analyze protein modifications one molecule at a time
- Country
Switzerland- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why UNOMR stands out
UNOMR is translating nanopore research from ETH Zurich into a benchtop analytical tool. The startup has secured CHF 300,000 in non-dilutive support and has worked with Nestlé on testing a protein glycosylation readout.
Peer-reviewed work from the underlying research program includes single-molecule nanopore studies published before company formation. That gives UNOMR a technical base that can be evaluated against a clear commercial use case: faster characterization of protein modifications.
What UNOMR is building
UNOMR is developing an adjustable nanopore sensor that measures individual protein molecules as they pass through a nanoscale opening. The electrical signal can reveal size and glycosylation, the attachment of sugar structures that can change how a protein behaves.
The benchtop format is aimed at pharmaceutical, biotechnology and nutrition research teams. By analyzing molecules one at a time, the platform is designed to complement bulk laboratory methods when teams need more detailed information about protein variants.
02
Asemblis
Building 3D human fat-tissue models for obesity drug development.
- Country
- Switzerland
- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
Why Asemblis stands out
Asemblis is turning tissue-engineering capability into a defined biopharma research product. Its commercial partnership with Viscofan BioEngineering covers Fibercoll-Flex collagen bioink and joint work on 3D tissue models for metabolic-drug research.
CEO Caio Valeriano also brings prior bioprinting commercialization experience from REGENHU. That combination of technical familiarity and early B2B partnership gives Asemblis a practical route from laboratory methods to paid research projects.
What Asemblis is building
Asemblis develops biofabricated human fat-tissue models for obesity and metabolic-disease research. Biofabrication uses cells and biomaterials to build structured living tissue models that can be studied outside the body.
The models are intended to help biopharma teams study inflammation, weight regain, muscle loss and safety signals before clinical trials. Asemblis scopes feasibility studies and pilots around defined research questions rather than selling a generic laboratory platform.
Developing lipid nanoparticle enzyme therapies for Pompe and other rare diseases.
- Country
- Switzerland
- Founded
- 2026
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why NanoZymeX stands out
NanoZymeX grew out of University of Basel research and has secured about CHF 1.4 million in grants and institutional support. Its peer-reviewed work reported more than a five-fold reduction in antibody response compared with free-enzyme formulations.
That evidence is directly connected to the product thesis: improve how replacement enzymes reach muscle while reducing immune recognition. The startup is therefore commercializing a delivery platform around two measurable constraints in enzyme-replacement therapy.
What NanoZymeX is building
NanoZymeX packages therapeutic enzymes inside lipid nanoparticles, tiny fat-based carriers used to protect and deliver biological cargo. Its lead program carries acid alpha-glucosidase for Pompe disease, a rare inherited disorder in which deficiency of that enzyme causes damaging glycogen buildup in muscle.
The particles are designed to increase uptake in skeletal muscle and diaphragm while shielding the enzyme from immune recognition. The same delivery platform is intended to support additional enzyme-deficiency diseases beyond Pompe disease.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
The three startups start from sophisticated research, but the proof each business needs is different. UNOMR has to show that a laboratory instrument produces useful information reliably, Asemblis has to show that its tissue models improve preclinical research decisions, and NanoZymeX has to advance a therapeutic platform through progressively stronger biological and clinical evidence.
That distinction matters for investors because technology maturity should be judged against the commercial endpoint. Early customer use can be a meaningful milestone for a research tool, while a therapy demands a longer evidence and manufacturing path. The underlying science may be equally deep even when the route to value looks very different.
Methodology
DealBio selected these startups from its coverage of early-stage health and longevity startups, focusing on Swiss biotech businesses that are translating research platforms into clearly defined products. The selection spans analytical tools, human tissue models and therapeutic delivery.
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.